Core Insights - AlphaTON Capital has not engaged in equity line financing with ATW Partners and maintains a low debt to equity ratio of 7% [1][11] - The company has transformed its balance sheet into a diversified portfolio of digital assets since its PIPE funding on September 25, 2025, focusing on the Telegram ecosystem [2][3] - AlphaTON Capital aims to create a closed-loop ecosystem that integrates various digital assets and applications, enhancing value across its operations [4][11] Strategic Initiatives - The company has launched the "AlphaTON World Tour" to educate institutional investors about the intersection of social media and decentralized finance [7] - AlphaTON is transitioning to an active operator model, incubating and acquiring cash-flowing businesses within the Telegram Mini-App economy [7] - The company is leveraging its legacy biotech assets while exploring innovations at the intersection of healthcare and blockchain technology [11] Financial Overview - AlphaTON has completed an acquisition of approximately $30 million in digital assets, with a current total asset value of $28.6 million [8] - The company has deployed 4 million TON into institutional staking contracts, generating predictable network rewards [11] - AlphaTON's treasury is currently trading at a 0.70 mNAV, indicating it is undervalued [8] Strategic Partnerships and Acquisitions - AlphaTON has executed a binding LOI with Animoca Brands to acquire a 51% equity interest in GAMEE, a mobile gaming platform [11] - The company has entered a joint venture with PagoPay and ALT5 Sigma to launch a co-branded TON Mastercard for crypto-to-fiat spending [11] - AlphaTON is collaborating with SingularityNET and others to develop decentralized AI infrastructure within the Telegram ecosystem [11] Leadership and Governance - The company has strengthened its leadership team with key appointments, including a new CFO, CPO, CTO, and CMO, to support its growth strategy [13][16] - The leadership team brings extensive experience in blockchain economics, commercial strategy, technical infrastructure, and digital asset communications [16]

Provides Detailed Breakdown of TON Holdings, Strategic Acquisitions, and Partnerships Following $71 Million Financing including $18.5 Million in equity financing from financing partnerships to launch the Artificial Intelligence Compute Program and Telegram Cocoon InitiativeNew York, NY, Nov. 19, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp. (Nasdaq: ATON) (“AlphaTON” or the “Company”), a specialized digital asset technology company focused on the Telegram ecosystem, today issued a comprehensive update to ...

San Francisco, United States, October 30th, 2025, Chainwire Hetu, a pioneer in decentralized science (DeSci) and financial infrastructure, today unveiled Hetu 3.0, an Ethereum-based AI-Native Monetary Stack that transforms verified intelligence into programmable capital — turning verified intelligence into liquid capital, bridging crypto liquidity with the AI economy, and introducing the first sovereign, society-owned AI currency. Ethereum-Based AI-Native Money Stack Built directly on Ethereum, Hetu 3.0 i ...

Company Overview - Galeon has 18 hospitals as paying customers for its EHR (Electronic Health Record) system [1] - The system protects 3 million patient records on the BNB Chain [1] - The company's market capitalization is $50 million [1] Financial Highlights - Galeon executed its first $100 thousand buyback on-chain from healthcare revenue [1] Technology and Integration - Galeon's system integrates with Samsung ultrasound devices [1] Doctor Network - 10 thousand doctors are using the Galeon system [1]

Core Insights - AlphaTON Capital has been recognized by Nasdaq for its innovative approach to funding cancer research through asset tokenization, marking a significant milestone in the intersection of digital assets and medical research funding [3][9] - The partnership with Cyncado Therapeutics aims to revolutionize cancer treatment financing by creating a transparent and accessible investment mechanism that connects global investors with oncology research programs [4][5] Company Overview - AlphaTON Capital is a specialized digital asset treasury company focused on developing the TON and Telegram ecosystem, while also engaging in blockchain-based healthcare financing [3][11] - The company implements a comprehensive treasury strategy that includes direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders [11] Innovative Funding Model - The collaboration with Cyncado Therapeutics addresses critical challenges in cancer research funding, including enhanced liquidity, transparent allocation of funds, reduced barriers to entry for investors, and accelerated research timelines [7][8] - Tokenized assets provide greater flexibility and market access, allowing for a broader audience participation in medical innovation [7] Market Recognition and Future Plans - The recognition from Nasdaq signals growing institutional acceptance of tokenized assets in regulated markets, positioning AlphaTON Capital as a leader in the emerging institutional digital asset space [9] - The company plans to expand its tokenization initiative to additional therapeutic areas and research institutions, with several partnerships currently in development [10]

Core Insights - AlphaTON Capital Corp is at the forefront of the decentralized science (DeSci) movement, leveraging its TON infrastructure to enhance cancer research, particularly in mesothelioma through a non-binding letter of intent for tokenization of single-indication economics for TT-4 [1][2][4] Company Overview - AlphaTON is the only Nasdaq-listed company that operates a strategic TON token treasury while advancing first-in-class immunotherapy assets, integrating decentralized science principles with medical research funding [2][3] - The company aims to democratize access to cancer research and align global stakeholders with patient outcomes through innovative financing mechanisms [4][8] Clinical Development - Cyncado Therapeutics, a wholly owned subsidiary of AlphaTON, is preparing for the clinical start-up of TT-4, an oral A2B receptor antagonist, with first-patient dosing expected in Q1 2026 [5][14] - The initial study will focus on safety dose-escalation in solid tumor patients, followed by a larger mesothelioma-focused study at major U.S. cancer centers [5] Scientific Validation - Preclinical data for TT-4 shows promising results, including 90% tumor growth inhibition in murine models when combined with anti-PD-1 therapy and 60% complete responses [7][6] - The drug's mechanism aims to neutralize immune suppression and enhance anti-tumor responses, demonstrating superior activity compared to existing checkpoint inhibitors [7] Decentralized Science Movement - The DeSci movement seeks to transform how scientific research is funded and shared, with AlphaTON's tokenization initiative positioning it as a leader in this space [8][9] - The company aims to enhance transparency in clinical development and create direct value alignment between research supporters and therapeutic success [13] Strategic Vision - AlphaTON's business model integrates its validator operations, ecosystem investments, and therapeutic programs to create synergies that accelerate the path from laboratory to patient [9][10] - The exploratory LOI for tokenization is designed to preserve traditional therapeutic development pathways while exploring innovative funding models [10]

Company Overview - Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on addressing underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases [4] - The company's portfolio includes innovative programs targeting PTSD, fibromyalgia, chronic pain, Alzheimer's disease, and multiple sclerosis, developed in collaboration with leading universities and laboratories [4] Investment in DeSci - Silo Pharma has made an initial purchase of ResearchCoin (RSC), the native token of ResearchHub, as part of its strategy to expand its digital assets treasury and capture long-term value from emerging multi-chain opportunities [1][2] - The investment in RSC aligns with the growing decentralized science (DeSci) movement, which emphasizes the use of blockchain technologies and token-based economics to modernize scientific research and collaboration [2] DeSci Movement - DeSci represents a transformative growth opportunity in the scientific research sector, with the potential to unlock a trillion-dollar global research economy currently tied up in grants, universities, and pharmaceutical pipelines [3] - By tokenizing research funding and intellectual property, DeSci can create profit opportunities years before traditional biotech exits, allowing investors to capture upside earlier and access new growth avenues in the biotech sector [3]